IMMUNIC, INC. — Director's Dealing 2024

Mar 6, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IMMUNIC, INC. (IMUX)
CIK: 0001280776
Period of Report: 2024-03-04

Reporting Person: Whaley Glenn (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-03-04	Stock Option	$7.37	D	15000	Disposed	2029-12-01	Common Stock (15000)	Direct
2024-03-04	Stock Option	$8.84	D	15000	Disposed	2030-04-29	Common Stock (15000)	Direct
2024-03-04	Stock Option	$12.30	D	30000	Disposed	2030-07-01	Common Stock (30000)	Direct
2024-03-04	Stock Option	$15.72	D	40000	Disposed	2031-03-01	Common Stock (40000)	Direct
2024-03-04	Stock Option	$10.73	D	70000	Disposed	2032-01-03	Common Stock (70000)	Direct
2024-03-04	Stock Option	$10.88	D	40000	Disposed	2032-03-10	Common Stock (40000)	Direct
2024-03-04	Stock Option	$3.40	D	10000	Disposed	2032-06-15	Common Stock (10000)	Direct
2024-03-04	Stock Option	$1.72	A	220000	Acquired		Common Stock (220000)	Direct

Footnotes

F1: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.